Priyanka Chopra Jonas and Crocs to Donate 50,000 Pairs of Classic Clogs to UNICEF
12.12.2019 16:00:00 EET | Business Wire | Press release
Crocs, Inc. (NASDAQ: CROX), in partnership with UNICEF Goodwill Ambassador Priyanka Chopra Jonas, today announced that 50,000 pairs of Crocs Classic clogs will be donated over the next year to underserved school children in Belize through UNICEF. This charitable contribution supports the actor’s joint mission to help children around the world and provide them with more opportunities to achieve an education.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191212005213/en/
In partnership with UNICEF Goodwill Ambassador and Crocs Global Brand Ambassador Priyanka Chopra Jonas, Crocs recently donated 25,000 pairs of Classic Clogs to underserved school children in Belize through UNICEF. This is the first of two donations to be made to this region through this partnership. A total of 50,000 pairs will ultimately be donated over the next year. (Photo: Business Wire)
Recently, Crocs announced award-winning actor, activist, and entrepreneur Priyanka Chopra Jonas would serve as a global brand ambassador for its 2020 “Come As You Are” marketing campaign. A special element of the partnership is this collaboration to jointly support UNICEF.
“At Crocs, we believe being comfortable in your own shoes is a first step to accessing quality education,” said Heidi Cooley, Vice President of Global Marketing, Crocs. “With this donation, we hope to deliver shoes to more than half of the student population attending primary and secondary school classes in Belize, while reducing the financial burden for their families.”
“As a global ambassador for UNICEF, I’m dedicated to connecting organizations that together can have a large and positive impact on children around the world,” said Priyanka Chopra Jonas. “Working with Crocs to distribute more than 50,000 pairs of their Classic Clogs will have a tremendous impact on school-age children in Belize, reducing barriers to education, and easing social and peer-related stressors that come with not having basic everyday resources that many take for granted.”
Barriers to education in Belize include poverty, disability, late entry, and inadequate preparation for primary school, among other factors. In November, members of UNICEF USA and Crocs visited Belize, where they distributed an initial 25,000 pairs of Crocs – the first of two parts of this donation – to students. A video documenting that journey and showing first-hand the positive impact of the contribution can be found linked here.
“UNICEF USA is grateful for Crocs’ generous shoe donation to help remove one of the barriers that can hinder school attendance in Belize, especially during early childhood education,” said Gabriella Morris, Senior Vice President of Strategic Partnerships, UNICEF USA. “Education is essential for children to live to their fullest potential, and together, we can help give each child the opportunity for quality education.”
About Crocs, Inc.
Crocs, Inc. (NASDAQ: CROX) is a world leader in innovative casual footwear for women, men, and children, combining comfort and style with a value that consumers know and love. Crocs’ proprietary Croslite™ material, a molded footwear technology, is included in the vast majority of Crocs’ collection and delivers extraordinary comfort with each step.
In 2019, Crocs declares that expressing yourself and being comfortable are not mutually exclusive. To learn more about Crocs or our global Come As You Are™ campaign, please visit www.crocs.com or follow @Crocs on Facebook, Instagram, and Twitter.
About UNICEF
The United Nations Children's Fund (UNICEF) works in more than 190 countries and territories to put children first. UNICEF has helped save more children’s lives than any other humanitarian organization, by providing health care and immunizations, clean water and sanitation, nutrition, education, emergency relief, and more. UNICEF USA supports UNICEF's work through fundraising, advocacy, and education in the United States. Together, we are working toward the day when no children die from preventable causes and every child has a safe and healthy childhood. For more information, visit www.unicefusa.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191212005213/en/
Contact information
Media Contacts:
Crocs
Melissa Layton
mlayton@crocs.com
UNICEF
Ann Reinking Whitener
areinking@unicefusa.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 05:00:00 EEST | Press release
Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated over the three years through 2028. The amount to be awarded to Helical Fusion will be announced following the formal grant
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28 [1]1.9.2026 00:35:00 EEST | Press release
ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will synergistically blend ITCI’s AI-led capabilities across Cloud, Data Analytics, PLM, SAP, enterprise transformation, industry-spe
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 22:07:00 EEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release
BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom